WO1998000117A2 - Nonocclusive drug delivery device and process for its manufacture - Google Patents
Nonocclusive drug delivery device and process for its manufacture Download PDFInfo
- Publication number
- WO1998000117A2 WO1998000117A2 PCT/US1997/011275 US9711275W WO9800117A2 WO 1998000117 A2 WO1998000117 A2 WO 1998000117A2 US 9711275 W US9711275 W US 9711275W WO 9800117 A2 WO9800117 A2 WO 9800117A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- foam layer
- drug delivery
- delivery device
- layer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
Definitions
- This invention relates to a nonocclusive drug delivery device and to a method for its manufacture.
- transdermal drug delivery device also variously referred to as a medical bandage, treatment pad, drug patch, etc.
- a drug depot or reservoir, in the form of a drug-storing matrix or carrier and an adhesive for attaching or securing the device to a surface of unbroken skin.
- a known drug delivery device is provided as a laminate of a thermoplastic microcellular foam layer carrying a measured quantity of drug or drug-containing composition, the upper surface of the foam layer being bonded to a thermoplastic film barrier layer and its lower surface possessing a contact adhesive. It has been found that a drug delivery device of this general construction may be liable to one or more drawbacks which preclude its effective use and practical acceptance. For example, unless the peel strength of the device is significantly less than the strength of the bond between the foam and barrier layers, on peeling the device from the skin, separation (i..e, delamination) of the foam and barrier layers may occur with portions of foam continuing to adhere to the skin.
- a nonocclusive drug delivery device which comprises: a) an open cell, flexible, oleophilic thermoplastic resin foam layer possessing upper and lower surfaces and predetermined adhesive, drug depot and drug migration barrier zones; b) a substantially moisture vapor permeable, liquid impermeable, flexible thermoplastic barrier layer bonded to the upper surface of the foam layer, the composite of the barrier and foam layers possessing a moisture vapor transmission rate of at least about 500 g/m 2 /24 h at 100% r.h and 32°C, the bond strength between the barrier layer and the foam layer being such as to resist separation of the barrier layer from the foam layer when the drug delivery device is subjected to the flexing and/or stretching forces normally encountered during its useful applied life; c) a pressure sensitive adhesive within the adhesive zone of the foam layer, the adhesive layer imparting a peel strength to the drug delivery device which is sufficiently below that of the bond strength between the foam layer and the barrier layer such that upon peeling the device from the skin, substantially all of the foam layer
- the device of this invention resists delamination when pulled from the skin and since its drug-containing component remains isolated from the adhesive component by a barrier zone, there is little, if any, likelihood of the drug composition reaching the adhesive and impairing its effectiveness.
- Fig. 1 is a cross-sectional view of one embodiment of a drug delivery device in accordance with the invention
- Figs. 2A-E schematically illustrate the principal stages in the manufacture of the drug delivery device of Fig. 1;
- Fig. 3 and 3 A illustrate the front and reverse sides of another embodiment of a drug delivery device herein provided as a facial mask for delivering one or more dermatologically and/or cosmetically beneficial active agents to facial skin; and, Fig. 4 illustrates another type of facial mask assembled in situ from several units of the drug delivery device of this invention each having its own configuration.
- a nonocclusive drug delivery device in accordance with this invention is shown generally in Fig. 1 at 10.
- the drug delivery device includes a substantially moisture vapor permeable, liquid impermeable, flexible thermoplastic barrier layer 11 bonded to, and generally coextensive with, upper surface 12 of open cell, flexible, oleophilic thermoplastic resin foam layer 13.
- Pressure sensitive adhesive 14 occupies a zone, or stratum, 15 on lower surface 16 of foam layer 13 for securing the drug delivery device to the skin.
- Drug composition 18 occupies drug depot zone 19 and is separated from adhesive zone 15 by barrier zone 20 which prevents or inhibits migration of the drug composition into adhesive 14.
- a release liner 17 seals and protects lower surface 16 of the foam layer during the residency of drug delivery device 10 within its package.
- the minimum strength of the bond between barrier layer 11 and foam layer 13 is one of several critical requirements of the drug delivery device of this invention and must be sufficient to prevent or inhibit separation, i.e., delamination, of the barrier layer from the foam layer under the sort of flexing and/or stretching forces that may be encountered during the useful life of the applied device.
- bond strengths of at least about 2 newtons (N), preferably at least about 3 N and more preferably at least about 5 N will generally provide satisfactory results in this regard.
- the bond between layers 11 and 13 may be achieved, it is necessary that the bond itself not result in a significant reduction in the moisture vapor transmission rate (MVTR) of the assembled layers.
- MVTR moisture vapor transmission rate
- a nonadhesive bonding technique e.g., one employing heat such as flame bonding that is capable of producing the desired bond strengths but without significantly reducing the MVTR of the composite fo ⁇ ned from layers 11 and 13.
- the MVTR of the barrier layer-foam layer subassembly will be at least about 500, preferably at least about 1000 and more preferably at least about 1200, g/m 2 /24 h at 100% r.h. and 32°C as measured by ASTM F1249-90.
- the contact adhesive must impart a peel strength to the drug delivery device, i.e., the amount of force required to peel the spent drug delivery device from the skin, which is less, preferably at least about 20 percent less and more preferably at least about 40 percent less, than such bond strength in order to prevent or minimize the separation of the barrier layer from the foam layer when the spent drug delivery device is peeled from the skin.
- Barrier layer 11 can be any thermoplastic film possessing an MVTR of one of the aforestated values.
- the barrier layer can be a polyurethane film possessing an average thickness of from about 0.5 to about 3.5 mils and preferably from about 1.0 to about 1.5 mils and a tensile strength of at least about 2500 psi and preferably at least about 3500 psi.
- Foam layer 13 in its as-manufactured state is an open cell, flexible, oleophilic foam that provides a stable matrix for the drug and its oleophilic delivery vehicle.
- stable matrix is meant that property of the foam which, owing to its oleophilic character, enables the foam to function not only as a depot, or reservoir, for the oleophilic drug composition, but confines the composition to zone 19 which is separated by barrier zone 20 from zone 15 occupied by pressure sensitive adhesive 14.
- the oleophilic characteristics of the foam layer prevent or inhibit migration of the drug composition into adhesive zone 15 where it could destroy or impair the effectiveness of adhesive 14 in securing the drug delivery device to the skin.
- Another advantageous characteristic of the drug delivery device herein is its ability to maintain continuous contact between the drug composition and the skin thus assuring that the drug will be constantly available at the site of its administration.
- the useful foams possess a density of from about 0.8 to about 8.0 and preferably from about 1.2 to about 4.8 lb/ft, a number of pores per inch of from about 30 to about 120 and preferably from about 60 to about 90, and can be fully or partially reticulated or nonreticulated.
- the average thickness of the foam layer can vary from about 30 to about 100 mils and for many applications is preferably from about 40 to about 70 mils.
- Suitable foams that can be employed herein include the untreated oleophilic (i.e. hydrophobic) open cell polyurethane foams disclosed in U.S. Patent No. 5,352,711, the contents of which are incorporated by reference herein.
- Pressure sensitive adhesive 14 can be selected from any of the known and conventional medical grade adhesives, e.g., those based on polyacrylic, polyvinylether, or polyurethane resins. It is an essential requirement that the amount of adhesive 14 applied to zone 15 of foam layer 13 be sufficient to achieve an acceptable level of adhesion of drug delivery device 10 to the skin but, as previously stated, with a resulting peel strength that is sufficiently below the bond strength between the barrier and foam layers. The amount of adhesive that will satisfy these criteria can be readily determined by simple and routine testing. Ordinarily, a medical grade polyacrylic adhesive such as Durotak ® (National Starch & Chemical Company, Bridgewater, NJ) or Gelva ® (Monsanto Inc. , St.
- Durotak ® National Starch & Chemical Company, Bridgewater, NJ
- Gelva ® Monsanto Inc. , St.
- a process for manufacturing the drug delivery device of this invention is schematically illustrated in Figs. 2A-E.
- barrier layer 11 is bonded to upper surface 12 of foam layer 13 employing a suitable bonding technique, preferably, a flame bonding procedure for the reason stated above.
- Flame bonding, or flame lamination involves the superficial softening or melting of upper surface 12 of foam layer 13 and while surface 12 is in this state, the application of barrier layer 11 thereto.
- Conditions of the flame bonding operation include the temperature of the flame, the proximity of surface 12 of the foam to the flame and the duration of exposure of this surface to the flame. The conditions that are employed for a particular flame bonding operation will depend on the properties of the foam and barrier layers, the bond strength desired and similar factors of which those skilled in the art are aware.
- a flame temperature of from about 1800 to about 2200°C, a distance from the flame to the upper surface of the foam of up to about 3 cm and an exposure time of such surface of from about 25 to about 40 milliseconds will usually provide the desired minimum bond strengths or better.
- a vacuum is applied to the lower surface of the foam layer and a molten thermoplastic layer intended to provide the barrier layer is cast upon the upper surface of the foam layer.
- the vacuum partially draws the cast layer of molten resin into the structure of the foam so that when the resin cools and solidifies, it provides the barrier layer securely bonded to the foam layer.
- the barrier layer/foam layer composite has been inverted (its orientation for this and the remaining operations shown) and a first, or temporary, release liner 30 with medical grade adhesive 14 applied thereto is brought into contact with zone 15 of lower surface 16 of foam layer 13. As shown in Fig.
- release liner 30 possesses cut-out portion 22 providing an opening, or "window", through which drug composition 18 is applied to exposed drug depot zone 19 of foam layer 13.
- Drug composition 18 is applied in a fluid or semi-fluid state which, e.g. , can be achieved, by heating, so that the composition spreads out somewhat from its initial point of application to zone 19. However, after reaching the maximum extent of its spread and hardening, drug composition 18 will be surrounded by barrier zone 20 lying between it and zone 15 through which contact adhesive 14 has infiltrated.
- drug-containing compositions can be incorporated into the drug depot zone of foam layer 13 of drug delivery device 10.
- drug is used herein in its broadest sense as referring to any substance or composition possessing therapeutically or medicinally beneficial activity and includes prescription and nonprescription pharmaceuticals, medicinals, medicaments, active ingredients of cosmetic and personal care preparations, and the like.
- Specific drugs that can be incorporated into drug composition 18 include topically delivered local anesthetics such as benzocaine, procaine hydrochloride, tetracaine, tetracaine hydrochloride, dibucaine, lidocaine, lidocaine hydrochloride, bupivicaine, dyclonin, etidocaine, mepivicaine, butamen picrate, dimethisoquin hydrochloride, cyclomethylcaine sulfate, and the like; analgesics and anti-inflammatory agents such as buprenorphin, butophanol tartrate, acetaminophen, fentanyl, mefenamic acid, flutenamic acid, diclofenac, oxyphenbutazone, phenybutazone, ibuprofen, flurbiprofen, naproxen, menthol, methyl salicylate, phenol, salicylic acid, benzyl alcohol, camphor, camphorated met
- Suitable diffusable oleophilic medium e.g., an ointment, paste or other oleophilic vehicle, in accordance with known established pharmaceutical formulating practice.
- suitable diffusable oleophilic medium e.g., an ointment, paste or other oleophilic vehicle, in accordance with known established pharmaceutical formulating practice.
- penetration enhancers that can be used herein are butylene glycol, capric acid, caproic acid, caprylic acid, caprylic/capric triglyceride, diethylene glycol, diethylene glycol monoethyl ether, glycerin, glyceryl dioleate, glycerol monooleate, glycerol trioleate, hexylene glycol, isopropylmyristate, isopropylpalmitate, linoleic acid, methyl laurate, oleic acid, oleyl alcohol, polyethylene glycol 200, polyethylene glycol dilaurate, propyl oleate, propylene glycol, squalene, and the like.
- Fig. 2D temporary release liner 30 is removed leaving adhesive 14 to remain incorporated in zone 15 of foam layer 13. Then, as shown in Fig. 2E, second, or final, release liner 40 is applied to lower surface 16 of the foam layer where it remains until such time as drug delivery device 10 is to be applied. If desired, drug delivery device 10 can be trimmed, e.g., along line 25.
- Drug delivery device 10 can also be fabricated by applying adhesive directly to the adhesive zone of the lower surface of the foam layer in the barrier layer/ foam layer composite and, following the evaporation of any solvent with which the adhesive may be formulated, applying the drug composition to the drug depot zone of the foam layer.
- This procedure lends itself to a continuous or semicontinuous manufacturing operation, e.g., feeding the barrier layer/foam layer composite in the form of a continuous or lengthy strip to an adhesive coating head where the adhesive is applied, passing the coated strip through an oven to accelerate evaporation of the solvent present in the adhesive, incorporating the drug into the drug depot zone, applying a final release liner and cutting the strip into individual drug delivery device units of desired length.
- Drug delivery device 10 can be manufactured in a variety of sizes and shapes and can be planar or three-dimensional.
- Figs. 3 and 3 A illustrate front and reverse views 40 and 50, respectively, of single piece facial mask 30 constructed in accordance with the present invention.
- Mask 30 can either be manufactured as an entirely planar unit or it can be formed, e.g., by vacuum molding or casting, into a unit shaped to fit the contours of the face.
- Contact adhesive 51 can be applied not only to an adhesive zone defined along the perimeter of the mask but to one or more additional locations to promote a more secure attachment of the mask to the face.
- Drug depot zone 52 can be filled with any one of several known and conventional drug compositions for treating dermatological disorders or improving cosmetic conditions such as dry skin, acne, keratoses, psoriasis, eczema, pruritus, age spots, lentigines, melasmas, wrinkles, warts, blemishes, hyperpigmentation, inflammatory dermatoses, skin changes associated with aging, etc.
- Fig. 4 illustrates in front view another type of facial mask 70 made up of several elements 71-74 each possessing, as shown in the cut-away view of element 74, the construction of drug delivery device 10. Elements 71-74 can be separated from each other (as shown) or they can be made to slightly overlap to provide more complete coverage. As in the case of facial mask 30 of Fig. 3, mask 70 can contain one or more dermatologically or cosmetically active agents for the treatment of facial skin.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10504343A JP2000514063A (en) | 1996-07-03 | 1997-07-02 | Non-occlusive drug delivery device and method of manufacturing the same |
EP97934025A EP0910352A2 (en) | 1996-07-03 | 1997-07-02 | Nonocclusive drug delivery device and process for its manufacture |
CA002259526A CA2259526A1 (en) | 1996-07-03 | 1997-07-02 | Nonocclusive drug delivery device and process for its manufacture |
AU37187/97A AU3718797A (en) | 1996-07-03 | 1997-07-02 | Nonocclusive drug delivery device and process for its manufacture |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/675,348 | 1996-07-03 | ||
US08/675,348 US5716621A (en) | 1996-07-03 | 1996-07-03 | Nonocclusive drug delivery device and process for its manufacture |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998000117A2 true WO1998000117A2 (en) | 1998-01-08 |
WO1998000117A3 WO1998000117A3 (en) | 1998-10-29 |
Family
ID=24710068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/011275 WO1998000117A2 (en) | 1996-07-03 | 1997-07-02 | Nonocclusive drug delivery device and process for its manufacture |
Country Status (6)
Country | Link |
---|---|
US (2) | US5716621A (en) |
EP (1) | EP0910352A2 (en) |
JP (1) | JP2000514063A (en) |
AU (1) | AU3718797A (en) |
CA (1) | CA2259526A1 (en) |
WO (1) | WO1998000117A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998053825A1 (en) * | 1997-05-27 | 1998-12-03 | Algos Pharmaceutical Corporation | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
US6280764B1 (en) | 1995-06-20 | 2001-08-28 | Lavipharm Laboratories Inc. | Device for topical treatment of acne and its method of manufacture |
WO2001076550A1 (en) * | 2000-04-10 | 2001-10-18 | Dr. Suwelack Skin & Health Care Ag | Face pack comprised of a sheet provided with detachably interconnected subcomponents |
JP2003503442A (en) * | 1999-07-05 | 2003-01-28 | イデア アクチェンゲゼルシャフト | Methods to improve transport across adaptive semi-permeable barriers |
WO2009085302A2 (en) | 2007-12-28 | 2009-07-09 | Newmedical Technology, Inc. | Method and multilayered device for controlled topical delivery of therapeutic agents to the skin |
US8591940B2 (en) | 2004-01-02 | 2013-11-26 | New Medical Technology Inc. | Method of treating scar tissue |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716621A (en) * | 1996-07-03 | 1998-02-10 | Pharmadyn, Inc. | Nonocclusive drug delivery device and process for its manufacture |
US6261405B1 (en) | 1997-06-27 | 2001-07-17 | Noven Pharmaceuticals, Inc. | Method and apparatus for making a patch |
US6096943A (en) * | 1998-01-09 | 2000-08-01 | Maiwald; Diane C | Skin wound protector |
US6183770B1 (en) | 1999-04-15 | 2001-02-06 | Acutek International | Carrier patch for the delivery of agents to the skin |
US7063859B1 (en) | 1999-04-28 | 2006-06-20 | Noven Pharmaceuticals, Inc. | Barrier film lined backing layer composition and method for topical administration of active agents |
US6277401B1 (en) | 1999-05-07 | 2001-08-21 | U.S. Dermatologics, Inc. | Drug delivery device |
US7083849B1 (en) * | 1999-06-04 | 2006-08-01 | 3M Innovative Properties Company | Breathable polymer foams |
US6117904A (en) * | 1999-09-03 | 2000-09-12 | Murphy; Donald M. | Treatment of pruritus |
US6541517B1 (en) * | 1999-09-03 | 2003-04-01 | Donald M. Murphy | Treatment of skin disorders |
US6492012B1 (en) * | 2000-02-02 | 2002-12-10 | Tilak M. Shah | Polymer penetrated porous substrates |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US6429231B1 (en) | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
US7074832B2 (en) * | 2001-09-24 | 2006-07-11 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
US8790688B2 (en) * | 2001-12-21 | 2014-07-29 | Coloplast A/S | Wound care device for local treatment of pain in a wound |
IL152486A0 (en) * | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US20070292355A1 (en) * | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
EP1556009B2 (en) * | 2002-10-25 | 2021-07-21 | Foamix Pharmaceuticals Ltd. | Cosmetic and pharmaceutical foam |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20050205086A1 (en) * | 2002-10-25 | 2005-09-22 | Foamix Ltd. | Retinoid immunomodulating kit and composition and uses thereof |
US20070292359A1 (en) * | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
US8486376B2 (en) * | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US20060193789A1 (en) * | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
US20080317679A1 (en) * | 2002-10-25 | 2008-12-25 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
US20070292461A1 (en) * | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US20050271596A1 (en) * | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
US9211259B2 (en) * | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US7704518B2 (en) * | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20050186142A1 (en) * | 2002-10-25 | 2005-08-25 | Foamix Ltd. | Kit and composition of imidazole with enhanced bioavailability |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US20080206161A1 (en) * | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
MXPA05010882A (en) * | 2003-04-08 | 2005-11-25 | Algorx Pharmaceuticals Inc | Preparation and purification of synthetic capsaicin. |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US20050042182A1 (en) * | 2003-08-13 | 2005-02-24 | Moshe Arkin | Topical compositions of urea |
US20050037040A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of urea and ammonium lactate |
US20050036953A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of ammonium lactate |
US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050025833A1 (en) * | 2003-07-16 | 2005-02-03 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20080069779A1 (en) * | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
JP2007508243A (en) * | 2003-08-04 | 2007-04-05 | フォーミックス エルティーディー. | Foam carrier containing amphiphilic copolymer gelling agent |
US8486374B2 (en) * | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
CA2536482C (en) * | 2003-08-25 | 2012-07-24 | Foamix Ltd. | Penetrating pharmaceutical foam |
WO2005027977A2 (en) * | 2003-09-22 | 2005-03-31 | Agis Industries (1983) Ltd. | Diclofenac compositions for the treatment of skin disorders |
US20050170138A1 (en) * | 2004-01-20 | 2005-08-04 | Berry Craig J. | Laminated thin film with increased dosage loading and improved physical film properties and method for manufacture |
US7666914B2 (en) * | 2004-06-03 | 2010-02-23 | Richlin David M | Topical preparation and method for transdermal delivery and localization of therapeutic agents |
US7704522B2 (en) * | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
CN101119713A (en) * | 2004-11-24 | 2008-02-06 | 阿尔高克斯制药公司 | Capsaicinoid gel formulation and uses thereof |
CN101528830A (en) | 2006-07-10 | 2009-09-09 | 麦德医像公司 | Super elastic epoxy hydrogel |
MX2009002536A (en) * | 2006-09-08 | 2009-04-14 | Foamix Ltd | Colored or colorable foamable composition and foam. |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
WO2009007785A2 (en) * | 2006-11-14 | 2009-01-15 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
US20080292560A1 (en) * | 2007-01-12 | 2008-11-27 | Dov Tamarkin | Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent |
DE102007025973A1 (en) * | 2007-06-04 | 2008-12-11 | Lts Lohmann Therapie-Systeme Ag | Storage stable laminate sections |
US8292862B2 (en) | 2007-08-03 | 2012-10-23 | Kimberly-Clark Worldwide, Inc. | Dynamic fitting body adhering absorbent article |
US8672911B2 (en) * | 2007-08-03 | 2014-03-18 | Kimberly-Clark Worldwide, Inc. | Body adhering absorbent article |
US7947027B2 (en) | 2007-12-28 | 2011-05-24 | Kimberly-Clark Worldwide, Inc. | Body adhering absorbent article |
US8062275B2 (en) | 2007-08-03 | 2011-11-22 | Kimberly Clark Worldwide, Inc. | Body adhering absorbent article and method for donning such article |
US8702672B2 (en) * | 2007-08-03 | 2014-04-22 | Kimberly-Clark Worldwide, Inc. | Body adhering absorbent article |
US8734413B2 (en) | 2007-08-03 | 2014-05-27 | Kimberly-Clark Worldwide, Inc. | Packaged body adhering absorbent article |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US20090130029A1 (en) * | 2007-11-21 | 2009-05-21 | Foamix Ltd. | Glycerol ethers vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
WO2009073734A2 (en) | 2007-12-03 | 2009-06-11 | Medipacs, Inc. | Fluid metering device |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
CA2712120A1 (en) * | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US20090291127A1 (en) * | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
US8329210B2 (en) * | 2008-09-23 | 2012-12-11 | Pharmapatch, Llc | Twin transdermal drug delivery patch |
EP2328582A4 (en) * | 2008-09-30 | 2012-02-22 | Teikoku Pharma Usa Inc | Transdermal extended-delivery donepezil compositions and methods for using the same |
US11147722B2 (en) * | 2008-11-10 | 2021-10-19 | Kimberly-Clark Worldwide, Inc. | Absorbent article with a multifunctional acrylate skin-adhesive composition |
US10022468B2 (en) * | 2009-02-02 | 2018-07-17 | Kimberly-Clark Worldwide, Inc. | Absorbent articles containing a multifunctional gel |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011032011A1 (en) | 2009-09-10 | 2011-03-17 | Medipacs, Inc. | Low profile actuator and improved method of caregiver controlled administration of therapeutics |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
DE102009048973A1 (en) * | 2009-10-09 | 2011-04-14 | Beiersdorf Ag | Transdermal therapeutic systems containing 4-n-butylresorcinol |
US20110172609A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Microneedle component assembly for drug delivery device |
US20110172645A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Wearable drug delivery device including integrated pumping and activation elements |
US20110172639A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Device and method for delivery of microneedle to desired depth within the skin |
US20110172637A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Drug delivery device including tissue support structure |
US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
US9500186B2 (en) | 2010-02-01 | 2016-11-22 | Medipacs, Inc. | High surface area polymer actuator with gas mitigating components |
US20110225705A1 (en) * | 2010-03-16 | 2011-09-22 | 3M Innovative Properties Company | Hearing protective device with moisture resistant earmuff sound absorbers |
US8952038B2 (en) | 2010-03-26 | 2015-02-10 | Philip Morris Usa Inc. | Inhibition of undesired sensory effects by the compound camphor |
DK2552245T3 (en) | 2010-03-26 | 2019-01-07 | Philip Morris Products Sa | INHIBITION OF SENSORY IRRITATION UNDER CONSUMPTION OF NON-SMOKABLE TOBACCO PRODUCTS |
WO2012061556A1 (en) | 2010-11-03 | 2012-05-10 | Flugen, Inc. | Wearable drug delivery device having spring drive and sliding actuation mechanism |
CA2906274A1 (en) | 2012-03-14 | 2013-09-19 | Medipacs, Inc. | Smart polymer materials with excess reactive molecules |
US11622929B2 (en) | 2016-03-08 | 2023-04-11 | Living Proof, Inc. | Long lasting cosmetic compositions |
MX2020012139A (en) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Compositions and methods for treating rosacea and acne. |
US10842729B2 (en) | 2017-09-13 | 2020-11-24 | Living Proof, Inc. | Color protectant compositions |
JP7244495B2 (en) | 2017-09-13 | 2023-03-22 | リビング プルーフ インコーポレイテッド | Long lasting cosmetic composition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5352711A (en) | 1991-08-12 | 1994-10-04 | The Proctor & Gamble Company | Method for hydrophilizing absorbent foam materials |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2858830A (en) * | 1956-10-01 | 1958-11-04 | Frank C Lowe | Surgical dressing |
US3025854A (en) * | 1957-09-06 | 1962-03-20 | William M Scholl | Finger bandage and method of making the same |
US3062210A (en) * | 1958-08-21 | 1962-11-06 | William M Scholl | Medicated pad or bandage and method of making the same |
US3157178A (en) * | 1961-12-14 | 1964-11-17 | Oneida Ltd | Dressing |
US3113568A (en) * | 1961-12-26 | 1963-12-10 | Eric K Erskine | Styptic bandage |
US3156242A (en) * | 1962-03-29 | 1964-11-10 | Johnson & Johnson | Flexible absorbent sheet |
US3665918A (en) * | 1970-01-12 | 1972-05-30 | Johnson & Johnson | Conformable adhesive sheet |
BE789739A (en) * | 1971-10-05 | 1973-04-05 | Lock Peter M | SURGICAL DRESSING |
US3849238A (en) * | 1972-04-07 | 1974-11-19 | S Ronel | Artificial skin |
US3900027A (en) * | 1974-01-02 | 1975-08-19 | Pall Corp | Process for preparing integral absorbent pad bandages and product |
US3949742A (en) * | 1974-09-20 | 1976-04-13 | Frigitronics, Inc. | Medical dressing |
US3978855A (en) * | 1975-01-17 | 1976-09-07 | Ionics Lyo Products Company | Polyurethane foam surgical dressing |
GB1562244A (en) * | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
US4753231A (en) * | 1981-02-13 | 1988-06-28 | Smith & Nephew Associated Companies P.L.C. | Adhesive wound dressing |
GB2102012B (en) * | 1981-07-02 | 1984-11-21 | Peter Maurice Lock | Wound dressing material |
US4450833A (en) * | 1981-12-02 | 1984-05-29 | Brooks William R | Method of dimensioning a polyurethane foam bandage |
US4538603A (en) * | 1982-04-22 | 1985-09-03 | E. R. Squibb & Sons, Inc. | Dressings, granules, and their use in treating wounds |
US4530353A (en) * | 1982-11-12 | 1985-07-23 | Johnson & Johnson Products, Inc. | Unitary adhesive bandage |
US4933184A (en) * | 1983-12-22 | 1990-06-12 | American Home Products Corp. (Del) | Menthol enhancement of transdermal drug delivery |
US4561435A (en) * | 1984-04-04 | 1985-12-31 | Chesebrough-Ponds, Inc. | Wound dressing |
US4773408A (en) * | 1985-01-04 | 1988-09-27 | E. R. Squibb & Sons, Inc. | Wound dressing |
US4773409A (en) * | 1985-09-20 | 1988-09-27 | E. R. Squibb & Sons, Inc. | Wound dressing |
US4810582A (en) * | 1985-11-12 | 1989-03-07 | Tyndale Plains-Hunter Ltd. | Hydrophilic polyurethane composition |
US4655210A (en) * | 1986-01-17 | 1987-04-07 | Seton Company | Foam bandage |
US4733659A (en) * | 1986-01-17 | 1988-03-29 | Seton Company | Foam bandage |
CA1326416C (en) * | 1986-08-25 | 1994-01-25 | Ralph Xavier Ewall | Polymeric wound dressings |
AU607172B2 (en) * | 1986-12-22 | 1991-02-28 | Cygnus, Inc. | Diffusion matrix for transdermal drug administration |
US5322695A (en) * | 1987-01-09 | 1994-06-21 | Hercon Laboratories Corporation | Moisture-vapor-permeable dressing |
US5098500A (en) * | 1988-02-01 | 1992-03-24 | Polymedica Industries, Inc. | Adhesive-faced porous absorbent sheet and method of making same |
US4906240A (en) * | 1988-02-01 | 1990-03-06 | Matrix Medica, Inc. | Adhesive-faced porous absorbent sheet and method of making same |
US4960594A (en) * | 1988-09-22 | 1990-10-02 | Derma-Lock Medical Corporation | Polyurethane foam dressing |
US5409472A (en) * | 1989-08-03 | 1995-04-25 | Smith & Nephew Plc | Adhesive polymeric foam dressings |
TW246682B (en) * | 1991-08-12 | 1995-05-01 | Procter & Gamble | |
US5246705A (en) * | 1992-04-08 | 1993-09-21 | Cygnus Therapeutic System | Occlusive, elastomeric backing materials in transdermal drug delivery systems, and associated methods of manufacture and use |
US5393528A (en) * | 1992-05-07 | 1995-02-28 | Staab; Robert J. | Dissolvable device for contraception or delivery of medication |
US5420197A (en) * | 1994-01-13 | 1995-05-30 | Hydromer, Inc. | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
JPH09124463A (en) * | 1995-10-31 | 1997-05-13 | Nitto Denko Corp | Transdermal patch |
US5716621A (en) * | 1996-07-03 | 1998-02-10 | Pharmadyn, Inc. | Nonocclusive drug delivery device and process for its manufacture |
-
1996
- 1996-07-03 US US08/675,348 patent/US5716621A/en not_active Expired - Fee Related
-
1997
- 1997-07-02 WO PCT/US1997/011275 patent/WO1998000117A2/en not_active Application Discontinuation
- 1997-07-02 AU AU37187/97A patent/AU3718797A/en not_active Abandoned
- 1997-07-02 EP EP97934025A patent/EP0910352A2/en not_active Withdrawn
- 1997-07-02 JP JP10504343A patent/JP2000514063A/en active Pending
- 1997-07-02 CA CA002259526A patent/CA2259526A1/en not_active Abandoned
- 1997-09-08 US US08/925,356 patent/US5891463A/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5352711A (en) | 1991-08-12 | 1994-10-04 | The Proctor & Gamble Company | Method for hydrophilizing absorbent foam materials |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6280764B1 (en) | 1995-06-20 | 2001-08-28 | Lavipharm Laboratories Inc. | Device for topical treatment of acne and its method of manufacture |
WO1998053825A1 (en) * | 1997-05-27 | 1998-12-03 | Algos Pharmaceutical Corporation | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
US6277398B1 (en) | 1997-05-27 | 2001-08-21 | Endo Pharmaceuticals Inc. | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
JP2003503442A (en) * | 1999-07-05 | 2003-01-28 | イデア アクチェンゲゼルシャフト | Methods to improve transport across adaptive semi-permeable barriers |
WO2001076550A1 (en) * | 2000-04-10 | 2001-10-18 | Dr. Suwelack Skin & Health Care Ag | Face pack comprised of a sheet provided with detachably interconnected subcomponents |
US8591940B2 (en) | 2004-01-02 | 2013-11-26 | New Medical Technology Inc. | Method of treating scar tissue |
WO2009085302A2 (en) | 2007-12-28 | 2009-07-09 | Newmedical Technology, Inc. | Method and multilayered device for controlled topical delivery of therapeutic agents to the skin |
EP2237772A2 (en) * | 2007-12-28 | 2010-10-13 | Newmedical Technologies, Inc. | Method and multilayered device for controlled topical delivery of therapeutic agents to the skin |
EP2237772A4 (en) * | 2007-12-28 | 2013-01-30 | Newmedical Technologies Inc | Method and multilayered device for controlled topical delivery of therapeutic agents to the skin |
Also Published As
Publication number | Publication date |
---|---|
US5891463A (en) | 1999-04-06 |
CA2259526A1 (en) | 1998-01-08 |
AU3718797A (en) | 1998-01-21 |
EP0910352A2 (en) | 1999-04-28 |
WO1998000117A3 (en) | 1998-10-29 |
US5716621A (en) | 1998-02-10 |
JP2000514063A (en) | 2000-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5891463A (en) | Nonocclusive drug delivery device and process for its manufacture | |
US6277401B1 (en) | Drug delivery device | |
US5505958A (en) | Transdermal drug delivery device and method for its manufacture | |
US7063859B1 (en) | Barrier film lined backing layer composition and method for topical administration of active agents | |
US3731683A (en) | Bandage for the controlled metering of topical drugs to the skin | |
US5965154A (en) | Adhesive matrix type transdermal patch and method of manufacturing same | |
JP3023989B2 (en) | Topical dressing, method of manufacturing topical dressing and use of topical dressing | |
US4769028A (en) | Pharmaceutical product, in medical bandage form | |
EP0674913B1 (en) | Non-occulusive adhesive patch for applying medication to the skin | |
US3734097A (en) | Therapeutic adhesive tape | |
EP0416842A1 (en) | Solid matrix system for transdermal drug delivery | |
WO2011105457A1 (en) | Adhesive skin patch | |
JP2004521085A (en) | Transdermal delivery system capable of titration | |
JP2007520262A (en) | Method for treating side effects associated with transdermal or topical drug delivery | |
EP0144486B1 (en) | Controlled-release drugsystem and process for preparing it | |
BRPI0621577A2 (en) | transdermal therapeutic system for volatile and / or thermolabile substances | |
EP0301589A2 (en) | Procaterol transdermal delivery system | |
US6586040B1 (en) | Method for manufacturing a laminate consisting of individual layers | |
EP1352649B1 (en) | Patch and production method thereof | |
JP4722628B2 (en) | Transdermal preparation | |
JPS6059208B2 (en) | complex preparation | |
EP1547600B1 (en) | Estradiol-containing patch | |
JPS5835113A (en) | Conjugated pharmaceutical preparation | |
WO1986000536A1 (en) | Bandage for sustained delivery of drugs | |
JPH0238570B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
ENP | Entry into the national phase |
Ref document number: 2259526 Country of ref document: CA Ref country code: CA Ref document number: 2259526 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997934025 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997934025 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997934025 Country of ref document: EP |